<DOC>
	<DOCNO>NCT00605475</DOCNO>
	<brief_summary>The purpose study evaluate , patient Type 2 Diabetes Mellitus , whether Canakinumab low Glycosylated hemoglobin / hemoglobin A1c ( HbA1c ) and/or peak glucose level response oral glucose tolerance test ( OGTT ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics ACZ885 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient age 18 70 year , type 2 diabetes mellitus ( noninsulin dependent diabetes ) least 6 month prior study start HbA1c 7.0 9.5 % On stable dose metformin monotherapy Stable body weight Poorly control type 2 diabetes ( low high blood sugar level , indicator poor control ) Acute infection prior dose Patients type 1 diabetes ( insulindependent diabetes ) Taking diabetes medication ( metformin ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>ACZ885</keyword>
	<keyword>IL-1B antagonist</keyword>
	<keyword>metformin</keyword>
	<keyword>glycemic control</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>